To read the full story, subscribe or sign in.

Addex shares fall 48% as recruitment delays scupper pivotal trial in Parkinson’s

June 17, 2022

Shares in Addex Therapeutics Ltd. (Zurich:ADXN) dropped 48% June 17 on news that the company had terminated a pivotal phase IIb/III study of dipraglurant as a potential treatment for dyskinesia in Parkinson’s disease.

BioWorld Clinical Neurology/Psychiatric

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Today's news in brief

BioWorld

BioWorld briefs for July 6, 2022.

Novavax vaccine shows its chops

BioWorld

Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 6.

Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

BioWorld

The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...

Upgrade your daily dose of biopharma and medtech news

Addex shares fall 48% as recruitment delays scupper pivotal trial in Parkinson’s